- Home
- SVRA
SVRA
Savara Inc.
as 04-01-2025 3:43pm EST
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $8.83 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.25 - $5.34 | Next Earning Date: | 03-27-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Savara Inc. (SVRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RAMSAY DAVID A | SVRA | Director | Mar 31 '25 | Buy | $2.78 | 150,000 | $416,250.00 | 2,513,642 |
Latest Savara Inc. News
SVRA Breaking Stock News: Dive into SVRA Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Savara Insider Bought Shares Worth $416,250, According to a Recent SEC Filing
Business Wire
6 days ago
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
MT Newswires
6 days ago
Savara Gets Up to $200 Million Loan From Hercules Capital
Business Wire
7 days ago
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
MT Newswires
7 days ago
Savara Files Biologics License Application to US FDA for Molbreevi to Treat Lung Disease
Business Wire
7 days ago
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Business Wire
16 days ago
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025
MT Newswires
a month ago
Savara Launches Test for Autoimmune Lung Disease in US; Shares Up Pre-Bell
Compare SVRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SVRA Savara Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.